HK Stock Market Move | ABISK-B(02256) rose by more than 4%, the results of the Phase III clinical trial of Pembrolizumab were announced. If Merck chooses to exercise its rights, it will increase the company's performance.

ABBISKO-B (02256) rose more than 8% intraday and, as of the time of writing, is up 4.15% at 4.27 Hong Kong dollars, with a trading volume of 6.335 million Hong Kong dollars. On the news front, He Yuyu announced that its subsidiary He Yuyu Medicine has achieved positive top-line results in the MANEUVER pivotal Phase 3 study of its CSF-1R small molecule inhibitor Pimicotinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT) patients, as well as the latest Phase 1 study results of Pimicotinib for treating TGCT. It is reported that in December 2023, He Yuyu Medicine reached an exclusive licensing agreement with Germany's Merck for Pimicotinib. CICC believes that the competitive TGCT and cGvHD data of Pimicotinib are expected to be important considerations for Merck exercising its overseas option, and exercising it could bring substantial milestone payments to He Yuyu in 2025, boosting the company's performance.